One platform. All studies. Full overview and control.
MedicalOne Connect is BAYOOMED’s digital platform for decentralized and hybrid clinical trials. The platform connects patients, study sites, sponsor teams and digital health technologies (DHTs) in a central infrastructure and creates the basis for high-quality, traceable and regulatory usable study data.
From patient adherence monitoring and ePRO capture to the integration of wearables and connected drug delivery devices, MedicalOne Connect supports the entire study process in a single platform.
Developed for modern clinical studies
Clinical trials are becoming increasingly decentralized, data-intensive and technology-driven. At the same time, the requirements for data quality, transparency and study monitoring are increasing. MedicalOne Connect supports sponsor teams in this process,
Central functions
Track income, dosage plans and therapy adherence in real time. Early warnings help to quickly identify deviations and initiate countermeasures.
Capture patient-reported endpoints digitally and integrate data from mobile applications, sensors and other DHTs.
MedicalOne Connect integrates wearables, medical sensors and connected drug delivery devices into a central platform. Data is recorded in a standardized way and made available for study evaluations.
Dashboards and evaluations provide sponsor teams with an up-to-date overview of study progress, adherence and data quality at all times.
All relevant data is documented in a traceable manner and can be tracked transparently throughout the course of the study.
MedicalOne Connect can be flexibly integrated into existing clinical trial processes and supports the connection of ePRO systems, DHTs, wearables, connected drug delivery devices and other digital data sources.
Open interfaces allow existing technologies to continue to be used and central study processes to be standardized at the same time.
The platform was developed to meet the requirements of modern clinical trials and supports key aspects of current FDA and EMA recommendations for the use of digital technologies in clinical trials. These include, among others: Traceability of source data, auditable documentation, etc.
